Compare FSP & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | LITS |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 36.3M |
| IPO Year | 2001 | 2003 |
| Metric | FSP | LITS |
|---|---|---|
| Price | $0.38 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 591.3K | 257.2K |
| Earning Date | 10-27-2026 | 11-10-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 15.69 | 13.81 |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $16.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $0.69 |
| 52 Week High | $1.05 | $1.99 |
| Indicator | FSP | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 36.17 |
| Support Level | $0.31 | $0.69 |
| Resistance Level | $0.40 | $1.24 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 9.57 | 22.59 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.